Unprecedented HAE Attack Rate Reductions with ORLADEYO® (berotralstat): A Breakthrough in Medical Science. BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...
$BioCryst製藥(BCRX.US)$BioCryst Pharmaceuticals Says New Analyses Of Real-world Use Of Oral, Once-daily Orladeyo (Berotralstat) Showed Patients Who Initiated Orladeyo Experienced Rapid, Substantial And Sustained Reductions In Attack Rates Through 18 Months Of Treatment
$BioCryst製藥(BCRX.US)$RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now have access to the fi...
$BioCryst製藥(BCRX.US)$BioCryst Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment) SEC announcement· 1 min ago
Investors are concerned about the company's path to profitability. If growth slows, profitability will be delayed. The company's negative equity could be a warning, though these losses are usually only on paper.
BioCryst Pharmaceuticals' low P/S ratio could be due to below-average future revenue growth. The future revenue might not justify a higher P/S, possibly straining a substantial share price increase. Some warning signs in its investment analysis are significant to consider.
$BioCryst製藥(BCRX.US)$BioCryst Reports Approval Of ORLADEYO (Berotralstat) By National Administration of Drugs, Foods, And Medical Devices (ANMAT) In Argentina
BioCryst製藥股票討論區
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
Don’t put much into analyst’s targets, but!
American Biotech Company Presents Data That Treats Hereditary Angioedema
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...
Update
News
Update/Blackrock!
SEC announcement· 1 min ago
News
暫無評論